Between-reagent lot verification is a routine laboratory exercise in which a set of samples is tested in parallel with an existing reagent lot and a candidate reagent lot (before the candidate lot is committed to test patient samples). The exercise aims to verify and maintain consistency in the analytical performance of a test. We examined the limitations of a routine betweenreagent lot verification procedure in detecting long-term analytical drift and looked for a more sensitive alternative.
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The core function of a clinical laboratory is to produce results that clinicians can rely on to make appropriate decisions. Most of the tests are quantitative in nature, and the laboratory is required to ensure that the measurement process does not produce results that deviate excessively from their "true" values. Many sources of variation can compromise the measurement process, one of which is the change of reagent lot.
Modern-day clinical laboratories generally use commercial reagents that are produced in large batches by manufacturers. A single batch of reagents produced under similar manufacturing conditions is assigned a particular lot number. Each lot of reagent is finite: a laboratory will need to switch to a different lot of reagent when the existing lot runs out. Because different lots of reagent are manufactured under slightly different conditions, they may react differently in the measurement process and lead to differences in patient results compared with earlier lots. An example is the use of antibodies of different binding characteristics, produced by different sources of animals, to formulate different lots of immunoassay reagents.
This shift in analytical performance may be small between consecutive reagent lots, but it may accumulate significantly over time. The Clinical and Laboratory Standards Institute has published a detailed guideline (EP26-A) on how clinical laboratories can verify the consistency of the analytical performance of a test between consecutive reagent lot changes (1 ) . In the guideline, the rejection rule is based on comparing the difference between the measured value and the target value against an appropriately derived critical difference. However, the protocol was not designed to monitor the long-term trends of lot-to-lot performance.
A recent report has highlighted the failure of current between-lot verification processes to identify a longterm, gradual positive drift in the analytical performance of a test for insulin-like growth factor 1 (IGF-1) 4 , which led to significant missed diagnoses and inappropriate clinical management (2 ) . The report motivated us to examine the limitations of the current between-lot verification processes in detecting long-term drifts in analyt-ical performance, as well as to explore other more sensitive approaches.
Limitations of Current Regression Approach
For a specific assay, let CV denote the analytical coefficient of variation of measurement. Let x i denote the measured value of patient i, and let X i denote the target value of patient i under the existing reagent lot. X i is assumed to be in the interval of the assay where CV is constant. The relationship between x i and X i can be described as follows:
where i ϳ N(0, X i ϫ CV) denotes the random measurement error under the existing reagent lot. Let y i denote the measured value of patient i, and let Y i denote the target value of patient i under the candidate reagent lot. Y i is assumed to be in the interval of the assay where CV is constant. The relationship between y i and Y i can be described as follows:
where i ϳ N(0, Y i ϫ CV) denotes the random measurement error under the candidate lot. The relationship between the 2 target values is Y i ϭ X i (1 ϩ ⌬) ϩ ␦, where ⌬ denotes the proportional bias and ␦ denotes the constant bias of the target value under the candidate lot compared with the existing reagent lot. Under the assumption of constant CV, we apply weighted Deming regression (WDR) for comparison of 2 reagent lots (3 ) . The values of 1 ϩ ⌬ and ␦ are estimated by deriving a regression line in the following form, on the basis of the measured values of the patients under the candidate lot (y) and the existing lot (x):
where ␤ is an estimate of 1 ϩ ⌬, and c is an estimate of ␦.
Linnet (4 ) analyzed the power of the acceptance/ rejection rule by computing the probabilities of rejecting candidate lot when ͉⌬͉ Ͼ ⌬ critical and ͉␦͉ Ͼ ␦ critical . On the basis of a 90% confidence level, he suggested the following for the critical value of ⌬:
where TEa is the allowable total analytic error. For example, on the basis of biological variation (https:// www.westgard.com/biodatabase1.htm), IGF-1 has a desirable TEa of 24% and a desirable CV of 7%. Therefore,
Considering the decision level of 250 g/L, which corresponds to an abnormal IGF-1 concentration for both men and women 31-35 years old, Linnet (4 ) suggests that the critical value of ␦ be computed as follows:
Assuming a range ratio (maximum concentration divided by minimum concentration) of 1600/16 ϭ 100 for IGF-1, it follows from Table 2 of Linnet (4 ) that approximately 20 samples are required to achieve a power of 0.9, or a probability of error detection of 90%.
Assuming that clinical laboratories can afford to use the number of samples suggested by Linnet (4 ) when performing lot-to-lot validation, existing regression approaches can detect significant differences between consecutive reagent lots. However, existing regression approaches do not detect lot-to-lot drifts that accumulate across multiple lot changes, especially when shifts between individual lots are low (2 ) .
To illustrate this issue, the power of WDR in detecting different magnitudes of proportional bias (Table 1) and constant bias (Table 2 ) between 2 consecutive reagent lots for IGF-1 was estimated through numerical simulations of 10 000 iterations, on the basis of a 90% confidence level. The values given in Table 1 are based on the assumption that 20 samples were used in each between-reagent lot verification exercise. Suppose there exists a proportional bias of 3% between the reagent lots. Table 1 shows that there is a high probability (75%) that this bias will not be detected by WDR. Similarly, there is a moderately high probability (67%) that a constant bias of 9 g/L will not be detected, as highlighted in Table 2 . Even if the shift were to be detected, it would be considered only as a shift between 2 reagent lots (with resulting rejection of the candidate reagent lot). The validation process would then be repeated by comparing the same existing reagent to a different candidate. reagent lot; the issue of detecting long-term drift would remain unresolved. Clearly, regression approaches, which study analytical biases only between 2 consecutive reagent lots, are not ideal for addressing longterm drift.
Algeciras-Schimnich et al. (2 ) used 2 approaches to study long-term analytical drift. The first approach was to compute the mean and median of the patient results measured under each reagent lot. These statistics were then analyzed for long-term trends. The second approach examined how the proportion of results below and above the reference interval varies between lots.
One limitation of both these approaches is that the mean and median of the patient results measured under each reagent lot are unreliable when the number of results is small, which can substantially increase the variability of the trend. This was illustrated in the study by AlgecirasSchimnich et al. (2 ) , in which the drift across reagent lots was much more obvious from the 101 095 data points obtained from Mayo Clinic than the 4573 data points obtained from the University of Virginia.
Second, both approaches are limited by the underlying assumption of a relatively stable patient population with unvarying mean characteristics during the study period. This may not be true in many instances in clinical practice. This same limitation also applies to the cumulative sum control chart approaches that have been proposed by Westgard et al. (5 ), Schoen et al. (6 ) , and Noyez (7 ) to quantitatively study long-term changes.
In this article, we propose an approach that is suitable for detecting long-term proportional and constant drifts in laboratories by use of relatively small sample sizes. It is also worth noting that our proposed approach does not require the laboratory to perform additional tests, but rather uses existing historical lot-to-lot verification results to study long-term drift.
Model Description DETECTING LONG-TERM PROPORTIONAL DRIFT
In this section, we propose a decision rule for detecting long-term proportional drift between reagent lots. Let ␤ i denote the slope estimate obtained by WDR when lots i and i ϩ 1 are compared. Observe that each lot-to-lot verification can be viewed as an independent trial, and the average of the slope estimates should be approximately 1 if there has been no long-term drift. To evaluate if there is long-term drift, we perform a Student t-test on the regression slopes obtained by computing the following proposed test statistic:
where SE ␤ is the standard error of ␤ i , n is the number of consecutive reagent lot comparisons evaluated, and median(SE ␤ ) is the median of the SE ␤ i values obtained. As in Linnet (8 ) , commercial software such as Analyse-it estimate SE ␤ i with the jackknife method (9 ) . The candidate lot n ϩ 1 is accepted if ͉t ␤ ͉ Յ t (␣/2,␤) , where ␣ is the probability of Type 1 error and ␤ denotes the critical value of the t-distribution with degrees of freedom ␤ Ϸ
where m is the number of patients samples used in each lot comparison (10 ) . Otherwise, the candidate lot can be presumed to exhibit a continuing, long-term trend that should be discussed with the manufacturer.
To evaluate our proposed decision rule, we estimated its power in detecting long-term analytical drift by computer simulations. To simulate the lot-to-lot validation procedure, 20 IGF-1 samples were randomly generated for each lot-to-lot validation. The target value of each patient was randomly sampled from a uniform distribution within the analytic range of IGF-1 (16 -1600 g/L). The measured values of each patient under the existing lot were then randomly sampled from a normal distribution centered at the patient's target value with a CV of 7%. The measured value of each patient under the candidate lot was sampled from a normal distribution, the mean of which was adjusted to account for the proportional bias ⌬. The slope estimate ␤ i for each lot-to-lot validation was obtained through WDR. Table 3 lists the powers of the proposed decision rule for different values of n and ⌬ calculated through numerical simulations of 10 000 iterations with 20 patient samples.
The results suggest that the proposed decision rule can be helpful in detecting long-term proportional drift. For example, we can be 90% confident that a lot-to-lot shift of Ն4% will be detected within 6 consecutive lotto-lot validations.
DETECTING LONG-TERM CONSTANT DRIFT
Next, we propose a decision rule for detecting long-term constant drift between reagent lots. If there is no longterm drift, the average of the intercept estimates should be approximately 0. Let c i denote the intercept estimate obtained by WDR when comparing between-reagent lots i and i ϩ 1. As in the previous section, we perform a Student t-test on the intercepts obtained by computing the following proposed test statistic: (8) where SE c i is the standard error of c i and median(SE c ) is the median of the SE c i values obtained. The candidate lot
Similarly, when a continued, long-term constant drift is detected, such a trend should be communicated to the manufacturer. Where possible, data from several laboratories should be examined to confirm the presence of such drifts.
We estimated the power of this decision rule in detecting long-term constant drift through computer simulations with the same parameters as above and 20 patient samples. The results are listed in Table 4 . The simulation results suggest that the proposed method is capable of detecting relatively minor long-term lot-to-lot constant drifts. For example, we are Ͼ90% confident that a lot-to-lot shift of Ն18 g/L will be detected within 6 lot-to-lot reagent verification exercises.
Application to Routine Clinical Data
The approach that we propose in this article was used to examine historical lot verification data for serum sodium at the National University Hospital, Singapore. Serum sodium was chosen to demonstrate the performance of this approach because it has very small within-person (0.6%) and between-person (0.7%) biological variations in the healthy population (https://www.westgard.com/ biodatabase1.htm). Furthermore, the serum sodium results obtained from the health screening clinic can be assumed to be representative of a healthy population. Any significant drift in serum sodium results in this population is likely to be attributable to a drift in analytical performance.
The serum sodium reagent lot verification data between February and July 2013 was extracted, and the regression coefficients between consecutive lots with WDR were derived. The reagent lot verification data are provided in Supplemental Table 1 , which accompa- nies the online version of this article at http://www. clinchem.org/content/vol61/issue10. The regression slope and intercept of these lot changes are provided in Table 5 . The data of failed lot verifications were omitted, as these lots were rejected and not used by the hospital. It was observed that a positive regression slope and a predominantly negative regression intercept were consecutively observed in the 6 accepted reagent lot changes between February and July 2013. This raises a concern whether there had been cumulative drift that exceeded acceptable limits.
With our proposed approach to study the 6 reagent lot changes between February and July 2013, the t-statistics obtained for proportional bias and constant bias are 1.97 and Ϫ1.74, respectively. The critical t-values (90% confidence level) for proportional bias and constant bias are 1.78 and 1.79, respectively. Hence, there is statistical evidence at a 90% confidence level that there was a cumulative drift in the analytical performance of serum sodium at the National University Hospital during this period.
Next, we examined the serum sodium results obtained from the Health Screening Clinic at the National University Hospital during the same period of time. The 3-month moving average of serum sodium measurements performed between January and December 2013 is illustrated in Fig. 1 . From this figure, we can see that the trend line is clearly not horizontal (i.e., there is a downward drift), which is consistent with the cumulative drift that we predicted from our proposed method. Because serum sodium is an electrolyte that is tightly regulated in an individual, the observed downward drift in the moving average is likely to be a result of cumulative analytical drift.
The low P values in our analysis above suggest the presence of a positive proportional bias and a negative constant bias. Although it is clear that these biases are not large (otherwise they would have been identified during individual lot verifications), the exact magnitudes of The solid line represents the trend line. The apparent delay in the downward trend of serum sodium is due to the lag effect of the 3-month moving average.
these biases are uncertain. To illustrate how a positive proportional bias and a negative constant bias can lead to a negative drift in average sodium measurements over time, consider an individual with a sodium measurement of 140 mmol/L under the old reagent. If the new reagent has a proportional bias of 0.02 and a constant bias of Ϫ3 mmol/L relative to the old reagent, the measurement of the same individual under the new reagent will be slightly lower:
Discussion
Our proposed method provides laboratory practitioners with a systematic way to identify long-term drift in analytical performance, which current regression methods have difficulties detecting. Hence, clinical laboratories can better maintain the consistency of their measurements by combining current regression-based reagent lot verification approaches to detect lot-to-lot shifts and our proposed approach to detect long-term analytical drifts. The strength of this approach includes the ability to objectively detect long-term analytical drift. It is also able to detect proportional and constant bias separately. The Student t-test described in this study has been programmed in an Excel spreadsheet with interpretive comments and is available in the online Supplemental Data.
We point out that a rejection rule on the basis of any of the 2 t-tests failing will have a higher Type 1 error (i.e., false rejection) than the Type 1 error that is expected when the rejection is based on an individual t-test alone. This issue can be easily addressed by adjusting the rejection criteria on the basis of the Sidák correction (11 ) to reduce the Type 1 error of each individual t-test so that the Type 1 error when the 2 t-tests are combined is as desired. For example, to achieve a Type 1 error of 10% when the rejection rule is based on any of the 2 t-tests failing, the Type 1 error of each test should be ␣ Ϸ 1 Ϫ ͱ͑1 Ϫ 0.1͒ ϭ 0.05. If the slope and coefficient are highly dependent (as in the serum sodium example discussed above), there is no need for the Sidák correction, as the conclusions of the 2 tests are likely to be similar.
Although the proposed approach can help detect long-term analytical drift, its performance is, in our opinion, less than ideal. For example, suppose that a 2% lotto-lot proportional shift is present in the IGF-1 measurements of a laboratory. The cumulative drift after 7 lot changes is (1.02 
